Home: Educational Supplement: Section 9

SELECT PUBLICATIONS

Aapro MS. Neoadjuvant therapy in breast cancer: Can we define its role? Oncologist 2001;6 Suppl 3:36-9. Abstract

Breslin TM et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000;18:3480-6. Abstract

Burcombe RJ et al. Evaluation of ER, PGR, HER2 and Ki67 as predictors of response to neoadjuvant chemotherapy for operable breast cancer. Proc ASCO 2001;Abstract 1896.

Cheung KL et al. Preoperative endocrine therapy for breast cancer. Endocrine-Related Cancer 1999;7(3):131-141. Full-Text

Cohen LF et al. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol 2000;24:1266-72. Abstract

Dixon JM et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: A randomized,double-blind,single-center study. Clin Cancer Res 2000;6(6):2229-35. Abstract

Dixon JM et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocrine-Related Cancer 1999;6(2):227-230. Full-Text

Dixon JM et al. Phase IIb study of neoadjuvant exemestane (EXE) in locally advanced breast cancer. Proc ASCO 2001;Abstract 1908.

El-Didi MH et al. Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management. Surg Today 2000;30:249-54. Abstract

Ellis MJ. Preoperative endocrine therapy for older women with breast cancer: Renewed interest in an old idea. Cancer Control 2000;7(6):557. Full-Text

Ellis MJ et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816. Abstract

Esserman LJ et al. Response to neoadjuvant therapy for breast cancer by MR imaging type, ER status, grade, and comparative hybridization. Proc ASCO 2001;Abstract 1866.

Geisler J et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001;7(5):1230-6. Abstract

Gianni L. Adjuvant and neoadjuvant treatment of breast cancer. Semin Oncol 2001;28(1):13-29. Abstract

Gregory RK et al. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast Cancer Res Treat 2000;59:171-5. Abstract

Hoff PM et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer 2000;88(9):2054-60. Abstract

Jakesz R. Comparison of pre- vs. postoperative chemotherapy in breast cancer patients: Four-year results of Austrian Breast & Colorectal Study Group (ABCSG) Trial 7. Proc ASCO 2001;Abstract

125. Kandioler-Eckersberger D et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50-6. Abstract

Krainick UE et al. Changes in expression of immunohistochemical parameters in breast cancer (BC) tissue after neoadjuvant therapy (NT). Is there a predictive value for response to treatment? Proc ASCO 2001;Abstract 3112.

Kuerer HM et al. Neoadjuvant chemotherapy in women with invasive breast carcinoma: Conceptual basis and fundamental surgical issues. J Am Coll Surg 2000;190(3):350-363. Abstract

Kurosumi M et al. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 2000;7:945-8. Abstract

Makris A et al. Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer 1999;85(9):1996-2000. Abstract

Malhotra V et al. Neoadjuvant and adjuvant chemotherapy (CT) with doxorubicin and docetaxel (DD) with surgery and radiation in locally advanced breast cancer. Proc ASCO 2001;Abstract 1771.

Mamounas EP, Fisher B. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol 2001;28:389-99. Abstract

Marwane B et al. Reduction of tumor size using neoadjuvant chemotherapy with docetaxel (TXT) and epirubicin (Epi) in primary operable breast cancer. Proc ASCO 2001;Abstract 1814.

Miles I et al. Neoadjuvant Arimidex or tamoxifen, alone or combined, for breast cancer (IMPACT): PgR-related reductions in proliferation marker KI67. Proc ASCO 2000;Abstract 360.

Nason KS et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000;89:2187-94. Abstract

Nefyodov LI et al. Comparative evaluation of blood plasma and tumor tissue amino acid pool in radiation or neoadjuvant preoperative therapies of breast cancer with the antitumor drug Ukrain. Drugs Exp Clin Res 2000;26:231-7. Abstract

Pierga JY et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000;83:1480-7. Abstract

Pujol P et al. Neoadjuvant tamoxifen for operable breast cancer: A need for phase III studies? Cancer Detect Prev 2000;24(5):445-51. Abstract

Rouzier R et al. Primary chemotherapy for operable breast cancer: Incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol 2001;19: 3828-35. Abstract

Smith IC, Miller ID. Issues involved in research into the neoadjuvant treatment of breast cancer. Anticancer Drugs 2001;12 Suppl 1:S25-9. Abstract

Smith IC et al. Current and potential chemotherapeutic agents used for induction chemotherapy in the treatment of breast cancer. Curr Pharm Des 2000;6(3):327-43. Abstract

Steger GG et al. Predictive factors for a complete pathological response (pCR) in primary breast cancer treated neoadjuvantly with a epirubicin/taxane+G-CSF regimen. Proc ASCO 2001:Abstract 154.

Terashima M et al. Breast-conservation treatment for patients with ductal carcinoma in situ. Oncol Rep 2000;7(6):1247-52. Abstract

Vlastos G et al. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer 2000;88:1417-24. Abstract

Top

Additional Sections:
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |

Additional Sections: